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30
Skin is a natural barrier yet despite this, is often the focus of permeation analysis in Formulations can be tailored to permeate skin at a rate suited to their requirements, 55 for example, they can be encouraged to permeate by the addition of permeation enhancers [14, 56 15] or discouraged by the addition of permeation retardants [16] . Interestingly it has been 57 found that a particular compound may act as an enhancer in one formulation yet a retardant in 58 another, further complicating the situation. However, what is not currently fully understood is 59 whether or not skin mimics, such as PDMS, behave in a similar manner to that seen in vivo 60 and if there is a pattern in their ability to enhance or retard permeation. Previous research 61 from within our group has investigated the effect of temperature on permeation using PDMS 62 and to a very limited extent, the effect of the presence of two surfactants, namely sodium 63 dodecyl sulfate and Brij 35, on two structurally similar paraben-based compounds [17] . In this 64 study it was found that the effect on permeation for these two compounds differed for the two 65 surfactants implying there was a surfactant-specific effect although general conclusions could 66 not be made from such a limited study. and Brij 35 (non-ionic).
131
As a control, the permeation of the model compounds through silicone membrane the cumulative amount of compound permeated after 6 hours (Q6), were calculated from the 139 data obtained using a flow-through diffusion cell system and are summarised in Tables 1 and   140 2. In the first set of experiments, permeation of benzocaine, benzotriazole, ibuprofen and and/or surfactant-drug interactions. One previous study from our group suggested surfactant-215 membrane interaction to be a triggering factor in the reduction of compound permeation [17] .
216
That study assumed that the hydrophobic tail of SDS was submerged within PDMS 217 membrane, thus, resulting in the charged head group exposed to the donor solution. percentage of the amount reduced by CTAB is different for each compound.
280
Although both SDS and CTAB create a barrier effect in compound permeability, the 281 overall trend they follow is different. From Fig. 1 and 2 , if the percentages of overall interaction between the anionic form of the compound and the cationic head group of CTAB.
299
In both scenarios, the compound would experience a reduction in transport through PDMS 300 membrane. However, the aforementioned circumstances may not be observed for lidocaine as
301
it forms a cation upon ionisation which is repelled by the cationic CTAB head. Unexpectedly, 
309
The third type of surfactant, investigated in this study, was a zwitterionic surfactant,
310
namely CHAPS. The effect of CHAPS on compound permeation is shown in Fig. 3 . 
362
In summary, the current study demonstrates that all five surfactants investigated here the surfactants being present in the donor solution at a concentration of 4 mM.
371
To confirm the surfactant-membrane interaction observed was an event that only 372 occurred in situ, i.e. was not the result of a permanent alteration to the membrane surface, 
